Search Results - "Bakker, Annette C"

Rethinking the nonprofit foundation: an emerging niche in the rare disease ecosystem by Bakker, Annette C, La Rosa, Salvatore

“…In recent years, medical foundations have become increasingly influential, and now play an instrumental and integral role in the research and development of…”
Get full text

Funding community collaboration to develop effective therapies for neurofibromatosis type 1 tumors by La Rosa, Salvatore, Browder, Vidya, Bakker, Annette C, Blakeley, Jaishri O, Verma, Sharad K, Wong, Ling M, Morris, Jill, Bora, Naba

“…The time from identifying a drug target to a new drug approval is often measured in decades and can take even longer for therapies to treat rare diseases. In…”
Get full text

Neurofibromatosis as a gateway to better treatment for a variety of malignancies by Bakker, Annette C, La Rosa, Salvatore, Sherman, Larry S, Knight, Pamela, Lee, Hyerim, Pancza, Patrice, Nievo, Marco

“…The neurofibromatoses (NF) are a group of rare genetic disorders that can affect all races equally at an incidence from 1:3000 (NF1) to a log unit lower for…”
Get full text

Creating a data resource: what will it take to build a medical information commons? by Deverka, Patricia A, Majumder, Mary A, Villanueva, Angela G, Anderson, Margaret, Bakker, Annette C, Bardill, Jessica, Boerwinkle, Eric, Bubela, Tania, Evans, Barbara J, Garrison, Nanibaa' A, Gibbs, Richard A, Gentleman, Robert, Glazer, David, Goldstein, Melissa M, Greely, Hank, Harris, Crane, Knoppers, Bartha M, Koenig, Barbara A, Kohane, Isaac S, La Rosa, Salvatore, Mattison, John, O'Donnell, Christopher J, Rai, Arti K, Rehm, Heidi L, Rodriguez, Laura L, Shelton, Robert, Simoncelli, Tania, Terry, Sharon F, Watson, Michael S, Wilbanks, John, Cook-Deegan, Robert, McGuire, Amy L

“…National and international public-private partnerships, consortia, and government initiatives are underway to collect and share genomic, personal, and…”
Get full text

CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies by Widemann, Brigitte C., Acosta, Maria T., Ammoun, Sylvia, Belzberg, Allan J., Bernards, Andre, Blakeley, Jaishri, Bretscher, Antony, Cichowski, Karen, Clapp, D. Wade, Dombi, Eva, Evans, Gareth D., Ferner, Rosalie, Fernandez-Valle, Cristina, Fisher, Michael J., Giovannini, Marco, Gutmann, David H., Hanemann, C. Oliver, Hennigan, Robert, Huson, Susan, Ingram, David, Kissil, Joe, Korf, Bruce R., Legius, Eric, Packer, Roger J., McClatchey, Andrea I, McCormick, Frank, North, Kathryn, Pehrsson, Minja, Plotkin, Scott R., Ramesh, Vijaya, Ratner, Nancy, Schirmer, Susann, Sherman, Larry, Schorry, Elizabeth, Stevenson, David, Stewart, Douglas R., Ullrich, Nicole, Bakker, Annette C., Morrison, Helen

“…The neurofibromatoses (NF) are autosomal dominant genetic disorders that encompass the rare diseases NF1, NF2, and schwannomatosis. The NFs affect more people…”
Get full text

Update from the 2013 international neurofibromatosis conference by Plotkin, Scott R., Albers, Anne C., Babovic-Vuksanovic, Dusica, Blakeley, Jaishri O., Breakefield, Xandra O., Dunn, Courtney M., Evans, D. Gareth, Fisher, Michael J., Friedman, Jan M., Giovannini, Marco, Gutmann, David H., Kalamarides, Michel, McClatchey, Andrea I., Messiaen, Ludwine, Morrison, Helen, Parkinson, David B., Stemmer-Rachamimov, Anat O., Van Raamsdonk, Catherine D., Riccardi, Vincent M., Rosser, Tena, Schindeler, Aaron, Smith, Miriam J., Stevenson, David A., Ullrich, Nicole J., van der Vaart, Thijs, Weiss, Brian, Widemann, Brigitte C., Zhu, Yuan, Bakker, Annette C., Lloyd, Alison C.

Get full text

Abstract 2057: Delivering on the Vision of Bench to Bedside: A Rare Disease Funding Community Collaboration to Develop Effective Therapies for Neurofibromatosis Type 1 Tumors by La Rosa, Salvatore, Bakker, Annette C., Browder, Vidya, Blakeley, Jaishri O., Verma, Sharad K., Wong, Ling M., Morris, Jill, Bora, Naba

“…The time from identifying a drug target to a new drug approval is often measured in decades and can take even longer for therapies to treat rare diseases. In…”
Get full text

Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation by SCHULZE-OSTHOFF, K, BAKKER, A. C, VANHAESEBROECK, B, BEYAERT, R, JACOB, W. A, FIERS, W

“…Structural mitochondrial damage accompanies the cytotoxic effects of several drugs including tumor necrosis factor (TNF). Using various inhibitors of…”
Get full text

Homotypic fusion between aggregated lysosomes triggered by elevated [Ca2+]i in fibroblasts by Bakker, A C, Webster, P, Jacob, W A, Andrews, N W

“…Previous studies demonstrated that microinjection of antibodies to the cytoplasmic domain of the lysosomal glycoprotein lgp120 induces aggregation of lysosomes…”
Get full text